Ceftriaxone and Haemostasis - a phase IV clinical study of FDA data

Summary:

Haemostasis is reported as a side effect among people who take Ceftriaxone (ceftriaxone sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Vancomycin, and have Febrile neutropenia.

The phase IV clinical study analyzes which people have Haemostasis when taking Ceftriaxone. It is created by eHealthMe based on reports of 40,872 people who have side effects when taking Ceftriaxone from the FDA, and is updated regularly.

What is Ceftriaxone?

Ceftriaxone has active ingredients of ceftriaxone sodium. It is often used in typhoid fever. eHealthMe is studying from 40,991 Ceftriaxone users. Check the latest studies of Ceftriaxone.

What is Haemostasis?

Haemostasis (stopping of bleeding) is found to be associated with 26 drugs and 103 conditions by eHealthMe. Check the latest studies of Haemostasis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

40,872 people reported to have side effects when taking Ceftriaxone.
Among them, 15 people (0.04%) have Haemostasis.

Among these 15 people:

How long have people been on Ceftriaxone when they have Haemostasis? *

What is the gender of people who have Haemostasis when taking Ceftriaxone? *

female: 73.33 %
male: 26.67 %

What is the age of people who have Haemostasis when taking Ceftriaxone? *

What are other drugs people take besides Ceftriaxone? *

What are other side effects people have besides Haemostasis? *

Nausea And Vomiting: 11 people, 73.33%
Wound Haemorrhage (bleeding wound): 11 people, 73.33%
Thrombocytopenia (decrease of platelets in blood): 11 people, 73.33%
Haemodynamic Instability (disturbances in the blood movement in our body): 11 people, 73.33%
Impaired Healing: 11 people, 73.33%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 11 people, 73.33%
Diarrhea: 11 people, 73.33%
Morganella Infection (infection by morganella morganii bacteria): 11 people, 73.33%
Anaemia (lack of blood): 11 people, 73.33%
Arterial Haemorrhage: 3 people, 20.00%

What are the existing conditions these people have? *

Rashes (redness): 10 people, 66.67%
Febrile Neutropenia (fever with reduced white blood cells): 10 people, 66.67%
Iron Deficiency Anaemia: 7 people, 46.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 6.67%
Rectal Cancer (cancer of rectum): 1 person, 6.67%
Arthropathy: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftriaxone and have Haemostasis?

- Check whether Haemostasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ceftriaxone:

Ceftriaxone (40,991 reports)

Haemostasis treatments and more:

Haemostasis (1,683 reports)

Browse all side effects of Ceftriaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Haemostasis:

Haemostasis (26 drugs)

Browse all the conditions that are associated with Haemostasis:

Haemostasis (103 conditions)

Related publications that referenced our studies

Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .
Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium (the active ingredients of Ceftriaxone) and Ceftriaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.